Clinical trial
Maximum Tolerated Dose of Lapatinib When Given With Carboplatin for Recurrent…
NCT00317434 · University of Alabama at Birmingham, Other · Terminated
Key facts
| NCT number | NCT00317434 |
|---|---|
| Title | Maximum Tolerated Dose of Lapatinib When Given With Carboplatin for Recurrent Ovarian Cancer |
| Official title | A Phase I Trial of Lapatinib in Combination With Carboplatin in Patients With Platinum Sensitive Recurrent Epithelial Ovarian Cancer |
| Lead sponsor | University of Alabama at Birmingham, Other |
| Collaborators | GlaxoSmithKline Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Ovarian Cancer |
| Intervention type | Drug |
| Interventions | lapatinib |
| Enrollment | 12 |
| Start date | Nov 1, 2005 |
| Primary completion | Mar 1, 2007 |
| Completion | Apr 1, 2007 |
| First posted | Apr 24, 2006 |
| Last update posted | Dec 15, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: